No description available.

Abnormal expression and signaling of the ErbB receptors is associated with the development and progression of several forms of cancer. In this thesis, new ErbB-targeting affibody molecules are evaluated regarding their cellular effects in vitro. Since ligand binding to an ErbB receptor might have an impact on the cell it is important to be aware of these effects as they may have consequences for the continued growth of the tumor when used in vivo. The affibody molecules are intended for tumor targeting with the prospect of clinical use in imaging or therapy. Three types of affibody molecules were studied, HER2-binding, EGFR-binding and bispecific binders that target both EGFR and HER2. The HER2-targeting (ZHER2:342)2 showed promising characteristics. It sensitized SKBR-3 cells to irradiation and decreased cell growth to the same extent as the clinically approved antibody Herceptin. The monomeric version, ZHER2:342, did not induce any large effects on intracellular signaling or biological outcome. This makes (ZHER2:342)2 interesting for therapy purposes, while ZHER2:342 may be better suited for imaging. The bispecific affibody molecules were all able to simultaneously bind to both EGFR and HER2, but none of the six constructs resulted in any large effects on cellular outcome. Interestingly, all three monovalent binders are more functional when positioned at the N-terminal part of the construct and the (S4G)3 linker renders higher affinity of the bispecific binders compared to (G4S)3. Tumors that co-express several ErbB receptors are often more aggressive and associated with a worse prognosis, suggesting that the total ErbB expression pattern might be more informative than the expression level of one receptor regarding cancer prognosis and prediction of response to targeted therapies. Bispecific ligands could thus be used as imaging agents with prognostic value. Another aspect of dual targeting is the possibility of increased tumor specificity since tumors are more likely than healthy tissue to express high amounts of two receptors.

Nukleinsäuren und Peptide erlauben es, Kontrolle über molekulare Prozesse auszuüben. In dieser Arbeit werden strukturgebende Elemente wie Coiled-Coil-Peptide oder PNA∙DNA-Strukturen genutzt, um Rezeptoren auf lebenden Zellen zu markieren und in ihrem Verhalten zu modulieren, oder cytosolische Proteine in ihrem Bindungsverhalten zu steuern. Im ersten Konzept wird die Interaktion des Coiled-Coil-Paars K3/E3 genutzt, um eine Transferreaktion, in welcher eine PNA-Sequenz vom K3-Donor auf den E3-Akzeptor übertragen wird, zu induzieren. Durch die Fusion des Akzeptorpeptids mit einem Rezeptor werden kovalente PNA-Rezeptorkonjugate auf der Oberfläche lebender Zellen geschaffen. Die Reaktion zwischen Thiol und Thioester erlaubt dabei einen schnellen Transfer. So wurden Rezeptoren aus der Familie der GPCR sowie der EGFR mit einem PNA-Strang versehen und durch fluoreszente PNA oder DNA selektiv markiert. Zusätzlich wurden verzweigte DNA-Architekturen mit mehreren Fluorophoren genutzt, um die Helligkeit der Markierung quantitativ zu erhöhen. Die PNA-EGFR-Konjugate wurden durch eine zwei Rezeptoren verbrückende Cy3-DNA adressiert und so zeitgleich markiert und dimerisiert. Dadurch wurde die Rezeptoraktivität gesteigert, was über Western Blot-, Immunofluoreszenz- und Fluoreszenzmikroskopieanalyse belegt wurde. In weiteren Ansätzen wurden Coiled-Coil-Systeme genutzt, um i) parallel zwei verschiedene Akzeptorpeptide mit verschiedenen Fluorophoren zu markieren und ii) Coiled-Coil-Peptide schaltbar zu machen. Durch die asymmetrische Verlängerung von K3/E3-Paaren mit Coiled-Coil-Sequenzen kann die Interaktion der Peptide an und aus geschaltet werden. Dies wurde sowohl in einem Fluoreszenzassay als auch in einer direkten Anwendung an der Syk-Kinase demonstriert. Die Liganden der Kinase wurden an den schaltbaren Peptiden angebracht und so die Affinität zur Syk-Kinase kontrolliert. / Nucleic acids and peptides can be used to obtain control over molecular processes within living cells. In this work, structural elements as coiled-coil peptides or PNA∙DNA-structures were used to label and modulate receptor behavior on living cells and to control ligand binding of cytosolic proteins. For the first concept the K3/E3-coiled-coil peptide pair was used to establish a proximity-guided, covalent transfer of a PNA strand from a K3-donor peptide onto the complementary E3-acceptor peptide. By fusion of the acceptor peptide to a receptor, PNA-receptor-conjugates were generated selectively on living cells. The native chemical ligation type of reaction allowed a fast PNA-transfer within minutes. Receptors from the family of GPCRs and the EGFR were tagged with a PNA-sequence and subsequently labeled by the addition of a fluorescent DNA or PNA. By recruiting branched DNA architectures which were decorated with several fluorophores, the total brightness of the labeling was increased quantitatively. A twice complementary Cy3-DNA was used to simultaneously label and dimerize the EGFR. Thereby, an artificially induced increase in receptor activity could be achieved, which was shown in Western Blot and immunofluorescence analysis as well as in fluorescence microscopy. In two other approaches coiled-coil peptides were used to i) label two different acceptor peptides simultaneously with two different dyes and ii) introduce coiled-coil peptides as part of a dynamic switchable system. Using an asymmetric coiled-coil elongation on the K3/E3 pair the interaction of both can be turned on and off. This was demonstrated in a fluorescence assay and applied to the Syk kinase, were Syk ligands were attached to the switchable peptides. Those ligands were changed from a bi- to a monovalent presentation status and thus the affinity of the Syk kinase towards its ligands can be controlled.